000154144 001__ 154144
000154144 005__ 20210129213837.0
000154144 0247_ $$2doi$$a10.1038/mp.2014.56
000154144 0247_ $$2ISSN$$a1476-5578
000154144 0247_ $$2ISSN$$a1359-4184
000154144 0247_ $$2Handle$$a2128/8462
000154144 0247_ $$2WOS$$aWOS:000349986700001
000154144 0247_ $$2altmetric$$aaltmetric:2404228
000154144 0247_ $$2pmid$$apmid:24888364
000154144 037__ $$aFZJ-2014-03537
000154144 082__ $$a610
000154144 1001_ $$0P:(DE-HGF)0$$aFrank, J.$$b0$$eCorresponding Author
000154144 245__ $$aIdentification of increased genetic risk scores for schizophrenia in treatment-resistant patients
000154144 260__ $$aLondon$$bMacmillan$$c2015
000154144 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1427449481_8870
000154144 3367_ $$2DataCite$$aOutput Types/Journal article
000154144 3367_ $$00$$2EndNote$$aJournal Article
000154144 3367_ $$2BibTeX$$aARTICLE
000154144 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154144 3367_ $$2DRIVER$$aarticle
000154144 520__ $$aSchizophrenia is a severe neuropsychiatric disorder that affects around 0.5–1% of the population. Research has shown that early intervention increases the likelihood of remission and reduces the severity of symptoms, as well as attenuates the decline in social and overall functioning.1Around 30% of patients fail to respond adequately to the usual antipsychotic medications, and are classified as being treatment resistant. These patients can be treated with the atypical antipsychotic clozapine, the only evidence-based pharmacotherapy for treatment-resistant schizophrenia. However, clozapine is associated with severe adverse events and is thus only prescribed in patients who have failed to respond to trials of two other antipsychotics. This process may take many years. Since an extended duration of untreated psychosis and lack of efficacy for the initial treatment are however associated with a poorer prognosis,6 identification of patients who will eventually require clozapine is an important goal for improving clinical outcome. Research to identify clinical predictors of response prior to treatment initiation has shown that premorbid social functioning (PSF) is among the most reliable measures (for a review see Schennach et al.6). Furthermore, reports of an association between a family history of psychosis and an unfavourable treatment response7 suggest the influence of genetic factors. However, few candidate gene studies have been conducted and their results are inconsistent.
000154144 536__ $$0G:(DE-HGF)POF3-571$$a571 - Connectivity and Activity (POF3-571)$$cPOF3-571$$fPOF III$$x0
000154144 588__ $$aDataset connected to CrossRef, juser.fz-juelich.de
000154144 7001_ $$0P:(DE-HGF)0$$aLang, M.$$b1
000154144 7001_ $$0P:(DE-HGF)0$$aWitt, S. H.$$b2
000154144 7001_ $$0P:(DE-HGF)0$$aStrohmaier, J.$$b3
000154144 7001_ $$0P:(DE-HGF)0$$aRujescu, D.$$b4
000154144 7001_ $$0P:(DE-Juel1)140234$$aCichon, S.$$b5
000154144 7001_ $$0P:(DE-HGF)0$$aDegenhardt, F.$$b6
000154144 7001_ $$0P:(DE-HGF)0$$aNöthen, M. M.$$b7
000154144 7001_ $$0P:(DE-HGF)0$$aCollier, D. A.$$b8
000154144 7001_ $$0P:(DE-HGF)0$$aRipke, S.$$b9
000154144 7001_ $$0P:(DE-HGF)0$$aNaber, D.$$b10
000154144 7001_ $$0P:(DE-HGF)0$$aRietschel, M.$$b11$$eCorresponding Author
000154144 773__ $$0PERI:(DE-600)1502531-7$$a10.1038/mp.2014.56$$p150-151$$tMolecular psychiatry$$v20$$x1476-5578$$y2015
000154144 8564_ $$uhttps://juser.fz-juelich.de/record/154144/files/FZJ-2014-03537.pdf$$yOpenAccess
000154144 8564_ $$uhttps://juser.fz-juelich.de/record/154144/files/FZJ-2014-03537.jpg?subformat=icon-144$$xicon-144$$yOpenAccess
000154144 8564_ $$uhttps://juser.fz-juelich.de/record/154144/files/FZJ-2014-03537.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000154144 8564_ $$uhttps://juser.fz-juelich.de/record/154144/files/FZJ-2014-03537.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000154144 909CO $$ooai:juser.fz-juelich.de:154144$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000154144 915__ $$0LIC:(DE-HGF)CCBYNCSA3$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-ShareAlike CC BY-NC-SA 3.0
000154144 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000154144 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000154144 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000154144 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154144 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154144 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000154144 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154144 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154144 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154144 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000154144 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000154144 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000154144 9141_ $$y2015
000154144 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)140234$$aForschungszentrum Jülich GmbH$$b5$$kFZJ
000154144 9130_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000154144 9131_ $$0G:(DE-HGF)POF3-571$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vConnectivity and Activity$$x0
000154144 9201_ $$0I:(DE-Juel1)INM-1-20090406$$kINM-1$$lStrukturelle und funktionelle Organisation des Gehirns$$x0
000154144 980__ $$ajournal
000154144 980__ $$aVDB
000154144 980__ $$aUNRESTRICTED
000154144 980__ $$aFullTexts
000154144 980__ $$aI:(DE-Juel1)INM-1-20090406
000154144 9801_ $$aFullTexts